Clinical Oversight Review Board (CORB) Criteria for Prescribing/ Criteria-Based Consultation (CBC) Criteria for Coverage

Fecal Microbiota Suspension (Rebyota)

Notes:

• Quantity Limits: Yes

Formulary **Fecal Microbiota Suspension 150mL (Rebyota 150mL)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

<u>Initiation (new start) criteria</u>: Formulary **Fecal Microbiota Suspension 150mL** (**Rebyota 150mL**) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Prescriber is a KPNW Infectious Disease Physician
- Patient is 18 years or older with history of 2 or more recurrent *Clostridioides Difficile* Infections (3 or more *C. Difficile* episodes)
- Most recent recurrent *Clostridioides Difficile* Infection is within the prior 8 weeks

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Formulary Fecal Microbiota

Suspension 150mL (Rebyota 150mL) will be covered on the prescription drug benefit for <u>2 months</u> when the following criteria are met:

- Prescriber is an Infectious Disease Physician
- Patient is 18 years or older with history of 2 or more recurrent Clostridioides
 Difficile Infections (3 or more C. Difficile episodes)
- Patient has received at least 1 dose of Fecal Microbiota Suspension 150mL (Rebyota 150mL) within the prior 8 weeks

kp.org

Revised: 03/09/2023 Effective: 05/18/2023

